We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

15 hedge funds and large institutions have $4M invested in Hepion Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 16 → 15 (-1)

26% less capital invested

Capital invested by funds: $5.43M → $4M (-$1.43M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
2
Calls
$21K
Puts
–
Net Calls
+$21K
Net Calls Change
-$25K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.97M
2
Osaic Holdings
Osaic Holdings
Arizona
+$16.4K
3
TRCT
Tower Research Capital (TRC)
New York
+$14.6K

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$653K
2
Renaissance Technologies
Renaissance Technologies
New York
-$140K
3
Morgan Stanley
Morgan Stanley
New York
-$76.5K
4
BlackRock
BlackRock
New York
-$20.9K
5
UBS Group
UBS Group
Switzerland
-$19.8K

HEPA Hedge Fund Activity: Q3 2023 in Review

15 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2023, worth a combined $4M — down 26% from $5.43M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of HEPA and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $2.97M. The largest seller was Octagon Capital Advisors, cutting an estimated $653K.

  • 15 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2023, down from 16 in Q2 2023.
  • Funds reported $4M of Hepion Pharmaceuticals stock for Q3 2023, down 26% quarter-over-quarter.
  • 1 fund opened new Hepion Pharmaceuticals positions in Q3 2023 and 2 closed out, a net change of -1 holder.
  • The largest Hepion Pharmaceuticals buyer in Q3 2023 was Armistice Capital, an estimated $2.97M added.
  • The largest Hepion Pharmaceuticals seller in Q3 2023 was Octagon Capital Advisors, an estimated $653K sold.

Based on aggregated 13F filings for Q3 2023.